Topical 0.05% Cyclosporine A Eyedrops for Treating Moderate-to-Severe Vernal KeratoconjunctivitisKenan Çalışır1, Taha Ayyıldız2, Ümit Çallı3
1Department of Ophthalmology, Horosan Public Hospital, Erzurum, Turkey.
2Department of Ophthalmology, Oltu Public Hospital, Erzurum, Turkey.
3Department of Ophthalmology, Umraniye Training and Research Hospital, İstanbul, Turkey.
This study aimed to investigate the efficacy of topical cyclosporine A (CsA) 0.05% in patients with moderate-to-severe vernal keratoconjunctivitis (VKC).Keywords: Cyclosporine A, topical, vernal keratoconjunctivitis
This retrospective study included 37 patients who were admitted to the clinic between January 2015 and December 2015. All patients were diagnosed with moderate-to-severe VKC and treated with topical CsA 0.05% (Restasis Allergan, Inc. CA, USA). The VKC diagnosis was based on patient history and typical clinical signs and symptoms. Sign and symptom scores of each patient were obtained at pretreatment and during treatment (1, 3, and 6 months).
Of the 37 patients, 20 (54.1%) were male and 17 (45.9%) were female. The mean age of the patients was 11.83 ± 4.70 years (624 years). The symptomsign and total scores of the patients were significantly reduced at 1, 3, and 6 months compared with baseline values. Symptomsign scores also significantly reduced from 1 month to 3 months and from 3 months to 6 months (P < 0.05).
Topical CsA 0.05% is an effective formulation used for treating moderate-to-severe VKC. It may reduce the need for steroids.
Kenan Çalışır, Taha Ayyıldız, Ümit Çallı. Topical 0.05% Cyclosporine A Eyedrops for Treating Moderate-to-Severe Vernal Keratoconjunctivitis. Med J Islamic World Acad Sci. 2016; 24(4): 107-111
Corresponding Author: Taha Ayyıldız, Türkiye